| Year |
Citation |
Score |
| 2022 |
Dinavahi SS, Chen YC, Punnath K, Berg A, Herlyn M, Foroutan M, Huntington ND, Robertson GP. Targeting WEE1/AKT restores p53-dependent NK cell activation to induce immune checkpoint blockade responses in 'cold' melanoma. Cancer Immunology Research. PMID 35439317 DOI: 10.1158/2326-6066.CIR-21-0587 |
0.417 |
|
| 2022 |
Dinavahi SS, Chen YC, Gowda R, Dhanyamraju PK, Punnath K, Desai D, Berg A, Kimball SR, Amin S, Yang JM, Robertson GP. Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development. International Journal of Molecular Sciences. 23. PMID 35408842 DOI: 10.3390/ijms23073481 |
0.373 |
|
| 2021 |
Chen YC, Dinavahi SS, Feng Q, Gowda R, Ramisetti S, Xia X, LaPenna KB, Chirasani VR, Cho SH, Hafenstein SL, Battu MB, Berg A, Sharma AK, Kirchhausen T, Dokholyan NV, ... ... Robertson GP, et al. Activating sphingosine-1-phospahte signaling in endothelial cells increases myosin light chain phosphorylation to decrease endothelial permeability thereby inhibiting cancer metastasis. Cancer Letters. PMID 33600895 DOI: 10.1016/j.canlet.2021.01.004 |
0.321 |
|
| 2020 |
Kardos GR, Gowda R, Dinavahi SS, Kimball S, Robertson GP. Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery. Frontiers in Oncology. 10: 834. PMID 32637352 DOI: 10.3389/Fonc.2020.00834 |
0.831 |
|
| 2020 |
Song C, Ge Z, Ding Y, Tan BH, Desai D, Gowda K, Amin SG, Gowda R, Robertson G, Yue F, Huang S, Spiegelman V, Payne J, Reeves M, Gurel Z, et al. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia. Blood. PMID 32396934 DOI: 10.1182/Blood.2019002655 |
0.395 |
|
| 2020 |
Gowda R, Robertson BM, Iyer S, Barry J, Dinavahi SS, Robertson GP. The role of exosomes in metastasis and progression of melanoma. Cancer Treatment Reviews. 85: 101975. PMID 32050108 DOI: 10.1016/J.Ctrv.2020.101975 |
0.389 |
|
| 2019 |
Dinavahi SS, Gowda R, Bazewicz CG, Battu MB, Lin JM, Chitren RJ, Pandey MK, Amin S, Robertson GP, Gowda K. Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents. European Journal of Medicinal Chemistry. 187: 111962. PMID 31887569 DOI: 10.1016/J.Ejmech.2019.111962 |
0.382 |
|
| 2019 |
Dinavahi SS, Gowda R, Gowda K, Bazewicz CG, Chirasani VR, Battu MB, Berg A, Dokholyan NV, Amin S, Robertson GP. Development of a novel multi-isoform ALDH inhibitor effective as an anti-melanoma agent. Molecular Cancer Therapeutics. PMID 31754071 DOI: 10.1158/1535-7163.Mct-19-0360 |
0.477 |
|
| 2019 |
Dinavahi SS, Bazewicz CG, Gowda R, Robertson GP. Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics. Trends in Pharmacological Sciences. PMID 31515079 DOI: 10.1016/J.Tips.2019.08.002 |
0.412 |
|
| 2019 |
Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, ... ... Robertson GP, et al. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Reports. 28: 1971-1980.e8. PMID 31433975 DOI: 10.1016/J.Celrep.2019.07.084 |
0.381 |
|
| 2019 |
Nicolae CM, O'Connor MJ, Schleicher EM, Song C, Gowda R, Robertson G, Dovat S, Moldovan GL. PARI (PARPBP) suppresses replication stress-induced myeloid differentiation in leukemia cells. Oncogene. PMID 30967629 DOI: 10.1038/S41388-019-0810-X |
0.381 |
|
| 2019 |
Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD. Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. Oncoimmunology. 8: e1539614. PMID 30713799 DOI: 10.1080/2162402X.2018.1539614 |
0.453 |
|
| 2018 |
DiSano JA, Huffnagle I, Gowda R, Spiegelman VS, Robertson GP, Pameijer CR. Loss of miR-155 upregulates WEE1 in metastatic melanoma. Melanoma Research. PMID 30499870 DOI: 10.1097/Cmr.0000000000000545 |
0.36 |
|
| 2018 |
Bazewicz CG, Dinavahi SS, Schell TD, Robertson GP. Aldehyde Dehydrogenase in Regulatory T Cell Development, Immunity and Cancer. Immunology. PMID 30387499 DOI: 10.1111/Imm.13016 |
0.375 |
|
| 2018 |
Gowda R, Dinavahi SS, Iyer S, Banerjee S, Neves RI, Pameijer CR, Robertson GP. Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29317343 DOI: 10.1016/J.Nano.2017.12.020 |
0.478 |
|
| 2018 |
Desai DH, Gowda R, Gowda K, Dinavahi SS, Robertson GP, Amin SG. Abstract 2806: Inhibition of melanoma development by Isatin analogs Cancer Research. 78: 2806-2806. DOI: 10.1158/1538-7445.Am2018-2806 |
0.474 |
|
| 2017 |
Dinavahi SS, Noory MA, Gowda R, Drabick JJ, Neves RI, Berg A, Robertson GP. Moving synergistically acting drug combinations to the clinic by comparing sequential versus simultaneous drug administrations. Molecular Pharmacology. PMID 29242354 DOI: 10.1124/Mol.117.110759 |
0.494 |
|
| 2017 |
Taylor MD, Bollt O, Iyer SC, Robertson GP. Metastasis suppressor 1 (MTSS1) expression is associated with reduced in-vivo metastasis and enhanced patient survival in lung adenocarcinoma. Clinical & Experimental Metastasis. PMID 29218652 DOI: 10.1007/S10585-017-9869-3 |
0.327 |
|
| 2017 |
Borland MG, Yao PL, Kehres EM, Lee C, Pritzlaff AM, Ola E, Wagner AL, Shannon BE, Albrecht PP, Zhu B, Kang BH, Robertson GP, Gonzalez FJ, Peters JM. Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis. Toxicological Sciences : An Official Journal of the Society of Toxicology. 159: 436-448. PMID 28962521 DOI: 10.1093/Toxsci/Kfx147 |
0.446 |
|
| 2017 |
Kuzu OF, Gowda R, Sharma A, Noory MA, Kardos G, Madhunapantula SV, Drabick JJ, Robertson GP. Identification of WEE1 as a Target to Make AKT Inhibition More Effective in Melanoma. Cancer Biology & Therapy. 0. PMID 28853983 DOI: 10.1080/15384047.2017.1360446 |
0.824 |
|
| 2017 |
Kuzu OF, Gowda R, Sharma A, Noory MA, Dinavahi SS, Kardos G, Drabick JJ, Robertson GP. Improving Pharmacological Targeting of AKT in Melanoma. Cancer Letters. PMID 28705772 DOI: 10.1016/J.Canlet.2017.07.001 |
0.831 |
|
| 2017 |
Kuzu OF, Gowda R, Noory MA, Robertson GP. Modulating cancer cell survival by targeting intracellular cholesterol transport. British Journal of Cancer. PMID 28697173 DOI: 10.1038/Bjc.2017.200 |
0.386 |
|
| 2017 |
Chen YC, Gowda R, Newswanger RK, Leibich P, Fell B, Rosenberg G, Robertson GP. Targeting Cholesterol Transport in Circulating Melanoma Cells to Inhibit Metastasis. Pigment Cell & Melanoma Research. PMID 28685959 DOI: 10.1111/Pcmr.12614 |
0.502 |
|
| 2017 |
Gowda R, Inamdar GS, Kuzu O, Dinavahi SS, Krzeminski J, Battu MB, Voleti SR, Amin S, Robertson GP. Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport. Oncotarget. PMID 28423677 DOI: 10.18632/Oncotarget.16002 |
0.398 |
|
| 2017 |
De Souza LM, Robertson BM, Robertson GP. Future of Circulating Tumor Cells in the Melanoma Clinical and Research Laboratory Settings. Cancer Letters. PMID 28163189 DOI: 10.1016/J.Canlet.2017.01.023 |
0.463 |
|
| 2017 |
Madhunapantula SV, Robertson GP. Targeting protein kinase-b3 (akt3) signaling in melanoma. Expert Opinion On Therapeutic Targets. PMID 28064546 DOI: 10.1080/14728222.2017.1279147 |
0.527 |
|
| 2016 |
Kuzu OF, Toprak M, Noory MA, Robertson GP. Effect of lysosomotropic molecules on cellular homeostasis. Pharmacological Research. PMID 28025106 DOI: 10.1016/J.Phrs.2016.12.021 |
0.375 |
|
| 2016 |
Gowda R, Kardos G, Sharma A, Singh S, Robertson GP. Nanoparticle-based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. Molecular Cancer Therapeutics. PMID 28003325 DOI: 10.1158/1535-7163.Mct-16-0285 |
0.791 |
|
| 2016 |
Gowda R, Sharma A, Robertson GP. Synergistic inhibitory effects of Celeoxib and Plumbagin on melanoma tumor growth. Cancer Letters. PMID 27769779 DOI: 10.1016/J.Canlet.2016.10.016 |
0.553 |
|
| 2016 |
Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, Mallon CA, Robertson G, Drabick JJ. Malignant melanoma-The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology. 106: 25-54. PMID 27637351 DOI: 10.1016/J.Critrevonc.2016.04.010 |
0.315 |
|
| 2016 |
Kuzu OF, Noory MA, Robertson GP. The Role of Cholesterol in Cancer. Cancer Research. 76: 2063-70. PMID 27197250 DOI: 10.1158/0008-5472.Can-15-2613 |
0.339 |
|
| 2016 |
Cheng Y, Ren X, Yuan Y, Shan Y, Li L, Chen X, Zhang L, Takahashi Y, Yang JW, Han B, Liao J, Li Y, Harvey H, Ryazanov A, Robertson GP, et al. eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis. Oncogene. PMID 27181208 DOI: 10.1038/onc.2016.166 |
0.344 |
|
| 2016 |
Brys A, Gowda R, Loriaux D, Robertson GP, Mosca PJ. Nanotechnology-Based Strategies for Combating Toxicity and Resistance in Melanoma Therapy. Biotechnology Advances. PMID 26826558 DOI: 10.1016/J.Biotechadv.2016.01.004 |
0.335 |
|
| 2015 |
Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, et al. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood. PMID 26219304 DOI: 10.1182/Blood-2015-06-651505 |
0.499 |
|
| 2015 |
Kardos GR, Robertson GP. Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell & Melanoma Research. 28: 501-19. PMID 26139519 DOI: 10.1111/Pcmr.12391 |
0.805 |
|
| 2015 |
Kardos GR, Wastyk HC, Robertson GP. Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway. Molecular Cancer Research : McR. PMID 26082174 DOI: 10.1158/1541-7786.Mcr-15-0048 |
0.832 |
|
| 2015 |
Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biology & Therapy. 16: 662-70. PMID 25806780 DOI: 10.1080/15384047.2015.1026507 |
0.359 |
|
| 2014 |
Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP. Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Molecular Cancer Therapeutics. 13: 2328-40. PMID 25082958 DOI: 10.1158/1535-7163.Mct-14-0357 |
0.561 |
|
| 2014 |
Kardos GR, Dai MS, Robertson GP. Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell & Melanoma Research. 27: 801-12. PMID 24807543 DOI: 10.1111/Pcmr.12259 |
0.82 |
|
| 2014 |
Kuzu OF, Gowda R, Sharma A, Robertson GP. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Molecular Cancer Therapeutics. 13: 1690-703. PMID 24688051 DOI: 10.1158/1535-7163.Mct-13-0868 |
0.423 |
|
| 2014 |
Gowda R, Madhunapantula SV, Kuzu OF, Sharma A, Robertson GP. Targeting multiple key signaling pathways in melanoma using leelamine. Molecular Cancer Therapeutics. 13: 1679-89. PMID 24688050 DOI: 10.1158/1535-7163.Mct-13-0867 |
0.582 |
|
| 2014 |
Mumford BS, Robertson GP. Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Molecular Diagnosis & Therapy. 18: 175-83. PMID 24297151 DOI: 10.1007/S40291-013-0071-2 |
0.46 |
|
| 2014 |
Khanna P, Chung CY, Neves RI, Robertson GP, Dong C. CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas. Oncogene. 33: 2898-908. PMID 23873025 DOI: 10.1038/Onc.2013.249 |
0.406 |
|
| 2013 |
Gowda R, Jones NR, Banerjee S, Robertson GP. Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. Journal of Nanomedicine & Nanotechnology. 4. PMID 25013742 DOI: 10.4172/2157-7439.1000184 |
0.489 |
|
| 2013 |
Madhunapantula SV, Sharma A, Gowda R, Robertson GP. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell & Melanoma Research. 26: 886-99. PMID 24034838 DOI: 10.1111/Pcmr.12156 |
0.562 |
|
| 2013 |
Wang Y, Xu Z, Guo S, Zhang L, Sharma A, Robertson GP, Huang L. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1919-29. PMID 23774794 DOI: 10.1038/Mt.2013.135 |
0.384 |
|
| 2013 |
Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI, El-Deiry WS. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle (Georgetown, Tex.). 12: 2132-43. PMID 23759587 DOI: 10.4161/Cc.25165 |
0.369 |
|
| 2013 |
Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. The American Journal of Pathology. 182: 1151-62. PMID 23416158 DOI: 10.1016/J.Ajpath.2012.12.019 |
0.52 |
|
| 2013 |
Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ. Current and future trials of targeted therapies in cutaneous melanoma. Advances in Experimental Medicine and Biology. 779: 223-55. PMID 23288642 DOI: 10.1007/978-1-4614-6176-0_10 |
0.543 |
|
| 2013 |
Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Molecular Cancer Therapeutics. 12: 3-15. PMID 23112250 DOI: 10.1158/1535-7163.Mct-12-0492 |
0.54 |
|
| 2013 |
Kardos GR, Robertson GP. Abstract 4395: Targeting ribosomal proteins for therapeutic inhibition of melanoma growth. Cancer Research. 73: 4395-4395. DOI: 10.1158/1538-7445.Am2013-4395 |
0.823 |
|
| 2012 |
Singh S, Sharma A, Robertson GP. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Research. 72: 5663-8. PMID 23139207 DOI: 10.1158/0008-5472.Can-12-1527 |
0.363 |
|
| 2012 |
Madhunapantula SV, Robertson GP. Chemoprevention of melanoma. Advances in Pharmacology (San Diego, Calif.). 65: 361-98. PMID 22959032 DOI: 10.1016/B978-0-12-397927-8.00012-9 |
0.38 |
|
| 2012 |
Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biology & Therapy. 13: 756-65. PMID 22669577 DOI: 10.4161/Cbt.20558 |
0.5 |
|
| 2012 |
Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell & Melanoma Research. 25: 259-74. PMID 22236408 DOI: 10.1111/J.1755-148X.2012.00970.X |
0.559 |
|
| 2012 |
Sharma A, Madhunapantula SV, Robertson GP. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opinion On Drug Metabolism & Toxicology. 8: 47-69. PMID 22097965 DOI: 10.1517/17425255.2012.637916 |
0.316 |
|
| 2011 |
Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biology & Therapy. 12: 1032-49. PMID 22157148 DOI: 10.4161/Cbt.12.12.18442 |
0.548 |
|
| 2011 |
Sudol M, Fritz JL, Tran M, Robertson GP, Ealy JB, Katzman M. Evaluation of a system to screen for stimulators of non-specific DNA nicking by HIV-1 integrase: application to a library of 50,000 compounds. Antiviral Chemistry & Chemotherapy. 22: 67-74. PMID 21984686 DOI: 10.3851/Imp1857 |
0.724 |
|
| 2011 |
Madhunapantula SV, Robertson GP. Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Research. 2011: 327923. PMID 21461351 DOI: 10.4061/2011/327923 |
0.52 |
|
| 2011 |
Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP. Melanoma prevention using topical PBISe. Cancer Prevention Research (Philadelphia, Pa.). 4: 935-48. PMID 21367959 DOI: 10.1158/1940-6207.Capr-10-0202 |
0.482 |
|
| 2011 |
Cheng Y, Ren X, Zhang Y, Patel R, Sharma A, Wu H, Robertson GP, Yan L, Rubin E, Yang JM. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Research. 71: 2654-63. PMID 21307130 DOI: 10.1158/0008-5472.Can-10-2889 |
0.489 |
|
| 2011 |
Mosca PJ, Robertson GP. Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. Cancer Biology & Therapy. 11: 581-3. PMID 21282973 DOI: 10.4161/Cbt.11.6.14697 |
0.389 |
|
| 2011 |
Zhang P, Ozdemir T, Chung CY, Robertson GP, Dong C. Sequential binding of αVβ3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. Journal of Immunology (Baltimore, Md. : 1950). 186: 242-54. PMID 21135163 DOI: 10.4049/Jimmunol.1000494 |
0.399 |
|
| 2011 |
Nguyen N, Sharma A, Nguyen N, Sharma AK, Desai D, Huh SJ, Amin S, Meyers C, Robertson GP. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prevention Research (Philadelphia, Pa.). 4: 248-58. PMID 21097713 DOI: 10.1158/1940-6207.Capr-10-0106 |
0.762 |
|
| 2010 |
Madhunapantula SV, Mosca P, Robertson GP. Steroid hormones drive cancer development. Cancer Biology & Therapy. 10: 765-6. PMID 20935464 DOI: 10.4161/Cbt.10.8.13531 |
0.374 |
|
| 2010 |
Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee WK, Robertson GP. KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. Journal of the National Cancer Institute. 102: 1131-47. PMID 20660366 DOI: 10.1093/Jnci/Djq218 |
0.78 |
|
| 2010 |
Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Research. 70: 6071-82. PMID 20610626 DOI: 10.1158/0008-5472.Can-09-4442 |
0.738 |
|
| 2010 |
Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochemical Pharmacology. 80: 624-37. PMID 20450891 DOI: 10.1016/J.Bcp.2010.04.029 |
0.509 |
|
| 2010 |
Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR, Stuart JM, Irby RB, Lee NH. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Molecular Cancer. 9: 98. PMID 20433755 DOI: 10.1186/1476-4598-9-98 |
0.388 |
|
| 2010 |
Huh SJ, Chung CY, Sharma A, Robertson GP. Macrophage inhibitory cytokine-1 regulates melanoma vascular development. The American Journal of Pathology. 176: 2948-57. PMID 20431030 DOI: 10.2353/Ajpath.2010.090963 |
0.76 |
|
| 2010 |
Mathew R, Jia W, Sharma A, Zhao Y, Clarke LE, Cheng X, Wang H, Salli U, Vrana KE, Robertson GP, Zhu J, Wang S. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 2702-15. PMID 20354136 DOI: 10.1096/Fj.09-148973 |
0.338 |
|
| 2010 |
Desai D, Madhunapantula SV, Gowdahalli K, Sharma A, Chandagaludoreswamy R, El-Bayoumy K, Robertson GP, Amin S. Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer. Bioorganic & Medicinal Chemistry Letters. 20: 2038-43. PMID 20153642 DOI: 10.1016/J.Bmcl.2009.09.071 |
0.409 |
|
| 2010 |
Sudol M, Tran M, Nowak MG, Flanagan JM, Robertson GP, Katzman M. A nonradioactive plate-based assay for stimulators of nonspecific DNA nicking by HIV-1 integrase and other nucleases. Analytical Biochemistry. 396: 223-30. PMID 19748478 DOI: 10.1016/J.Ab.2009.09.012 |
0.729 |
|
| 2010 |
Sk UH, Gowda ASP, Gimbor MA, Gowda R, Robertson GP, Spratt TE, Yun JK, Amin S, Sharma AK. Abstract 742: Development of novel naphthalimide derivatives as potential melanoma therapeutics Cancer Research. 70: 742-742. DOI: 10.1158/1538-7445.Am10-742 |
0.43 |
|
| 2009 |
Mounir Z, Krishnamoorthy JL, Robertson GP, Scheuner D, Kaufman RJ, Georgescu MM, Koromilas AE. Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Science Signaling. 2: ra85. PMID 20029030 DOI: 10.1126/Scisignal.2000389 |
0.466 |
|
| 2009 |
Dong C, Robertson GP. Immunoediting of leukocyte functions within the tumor microenvironment promotes cancer metastasis development. Biorheology. 46: 265-79. PMID 19721189 DOI: 10.3233/Bir-2009-0545 |
0.505 |
|
| 2009 |
Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell & Melanoma Research. 22: 388-99. PMID 19493316 DOI: 10.1111/J.1755-148X.2009.00581.X |
0.776 |
|
| 2009 |
Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell & Melanoma Research. 22: 400-19. PMID 19493313 DOI: 10.1111/J.1755-148X.2009.00585.X |
0.498 |
|
| 2009 |
Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1674-85. PMID 19208796 DOI: 10.1158/1078-0432.Ccr-08-2214 |
0.787 |
|
| 2009 |
Gaitonde S, De SK, Tcherpakov M, Dewing A, Yuan H, Riel-Mehan M, Krajewski S, Robertson G, Pellecchia M, Ronai Z. BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell & Melanoma Research. 22: 187-95. PMID 19175524 DOI: 10.1111/J.1755-148X.2009.00544.X |
0.486 |
|
| 2009 |
Salli U, Fox TE, Carkaci-Salli N, Sharma A, Robertson GP, Kester M, Vrana KE. Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells and Development. 18: 55-65. PMID 18393629 DOI: 10.1089/Scd.2007.0271 |
0.333 |
|
| 2009 |
Madhunapantula SV, Sharma A, Chandagalu RGD, Robertson GP. Abstract B220: Identification and characterization of kinase targets to treat melanoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B220 |
0.541 |
|
| 2009 |
Chung C, Madhunapantula SV, Meyers C, Desai D, Amin S, Robertson GP. Abstract A96: Melanoma chemoprevention using topical PBISe Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A96 |
0.494 |
|
| 2009 |
Sharma A, Nguyen N, Nguyen N, Sharma A, Desai D, Huh SJ, Amin S, Robertson GP. Abstract A93: Topical ISC‐4 for the prevention of melanoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A93 |
0.748 |
|
| 2008 |
Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoğlu EI, Tabaković A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Letters. 8: 4116-21. PMID 19367878 DOI: 10.1021/Nl802098G |
0.313 |
|
| 2008 |
Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S. Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. Journal of Medicinal Chemistry. 51: 7820-6. PMID 19053750 DOI: 10.1021/Jm800993R |
0.769 |
|
| 2008 |
Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Research. 68: 7638-49. PMID 18794153 DOI: 10.1158/0008-5472.Can-07-6614 |
0.814 |
|
| 2008 |
Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3571-81. PMID 18519791 DOI: 10.1158/1078-0432.Ccr-07-4881 |
0.807 |
|
| 2008 |
Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Molecular Cancer Therapeutics. 7: 1297-308. PMID 18483317 DOI: 10.1158/1535-7163.Mct-07-2267 |
0.8 |
|
| 2008 |
Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Research. 68: 3429-39. PMID 18451171 DOI: 10.1158/0008-5472.Can-07-5867 |
0.492 |
|
| 2008 |
Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Research. 68: 5-8. PMID 18172288 DOI: 10.1158/0008-5472.Can-07-2038 |
0.498 |
|
| 2008 |
Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology. 243: 236-43. PMID 18054822 DOI: 10.1016/J.Tox.2007.10.023 |
0.394 |
|
| 2008 |
Lung HL, Lo CC, Wong CC, Cheung AK, Cheong KF, Wong N, Kwong FM, Chan KC, Law EW, Tsao SW, Chua D, Sham JS, Cheng Y, Stanbridge EJ, Robertson GP, et al. Identification of tumor suppressive activity by irradiation microcell-mediated chromosome transfer and involvement of alpha B-crystallin in nasopharyngeal carcinoma. International Journal of Cancer. Journal International Du Cancer. 122: 1288-96. PMID 18027848 DOI: 10.1002/Ijc.23259 |
0.33 |
|
| 2007 |
Sharma A, Robertson GP. Models of melanoma metastasis: using a transient siRNA-based protein inhibition strategy in mice to validate the functional relevance of pharmacological agents. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit 14.6. PMID 21948165 DOI: 10.1002/0471141755.Ph1406S38 |
0.515 |
|
| 2007 |
Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Research. 67: 5814-20. PMID 17575149 DOI: 10.1158/0008-5472.Can-06-4233 |
0.453 |
|
| 2007 |
Robertson GP. Mig-7 linked to vasculogenic mimicry. The American Journal of Pathology. 170: 1454-6. PMID 17456752 DOI: 10.2353/Ajpath.2007.070127 |
0.436 |
|
| 2007 |
Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Research. 67: 3626-36. PMID 17440074 DOI: 10.1158/0008-5472.Can-06-4234 |
0.576 |
|
| 2006 |
Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, Robertson GP. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Research. 66: 8200-9. PMID 16912199 DOI: 10.1158/0008-5472.Can-06-0809 |
0.81 |
|
| 2006 |
Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. The Journal of Biological Chemistry. 281: 25447-56. PMID 16803888 DOI: 10.1074/Jbc.M605273200 |
0.358 |
|
| 2005 |
Croushore JA, Blasiole B, Riddle RC, Thisse C, Thisse B, Canfield VA, Robertson GP, Cheng KC, Levenson R. Ptena and ptenb genes play distinct roles in zebrafish embryogenesis. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 234: 911-21. PMID 16193492 DOI: 10.1002/Dvdy.20576 |
0.382 |
|
| 2005 |
Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Reviews. 24: 273-85. PMID 15986137 DOI: 10.1007/S10555-005-1577-9 |
0.545 |
|
| 2005 |
Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3465-74. PMID 15867249 DOI: 10.1158/1078-0432.Ccr-04-1770 |
0.42 |
|
| 2005 |
Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research. 65: 2412-21. PMID 15781657 DOI: 10.1158/0008-5472.Can-04-2423 |
0.817 |
|
| 2004 |
Wang S, Robertson GP, Zhu J. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene. 343: 69-78. PMID 15563832 DOI: 10.1016/J.Gene.2004.09.006 |
0.445 |
|
| 2004 |
Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research. 64: 7002-10. PMID 15466193 DOI: 10.1158/0008-5472.Can-04-1399 |
0.587 |
|
| 2004 |
Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. The Journal of Biological Chemistry. 279: 29930-7. PMID 15150271 DOI: 10.1074/Jbc.M402591200 |
0.437 |
|
| 2003 |
Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research. 63: 5198-202. PMID 14500344 |
0.378 |
|
| 2003 |
Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Research. 63: 2881-90. PMID 12782594 |
0.801 |
|
| 2000 |
Nord B, Platz A, Smoczynski K, Kytölä S, Robertson G, Calender A, Murat A, Weintraub D, Burgess J, Edwards M, Skogseid B, Owen D, Lassam N, Hogg D, Larsson C, et al. Malignant melanoma in patients with multiple endocrine neoplasia type 1 and involvement of the MEN1 gene in sporadic melanoma. International Journal of Cancer. 87: 463-7. PMID 10918183 DOI: 10.1002/1097-0215(20000815)87:4<463::Aid-Ijc1>3.0.Co;2-8 |
0.406 |
|
| 1999 |
Robertson GP, Huang HJ, Cavenee WK. Identification and validation of tumor suppressor genes. Molecular Cell Biology Research Communications : McBrc. 2: 1-10. PMID 10527883 DOI: 10.1006/Mcbr.1999.0141 |
0.37 |
|
| 1998 |
Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 95: 9418-23. PMID 9689095 DOI: 10.1073/Pnas.95.16.9418 |
0.42 |
|
| 1997 |
Robertson GP, Hufford A, Lugo TG. A panel of transferable fragments of human chromosome 11q. Cytogenetics and Cell Genetics. 79: 53-9. PMID 9533012 DOI: 10.1159/000134682 |
0.331 |
|
| 1996 |
Miele ME, Robertson G, Lee JH, Coleman A, McGary CT, Fisher PB, Lugo TG, Welch DR. Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6. Molecular Carcinogenesis. 15: 284-99. PMID 8634087 DOI: 10.1002/(Sici)1098-2744(199604)15:4<284::Aid-Mc6>3.0.Co;2-G |
0.307 |
|
| 1995 |
Robertson G, Coleman A, Lugo T. Mechanisms of melanoma cell growth and tumor suppression by human chromosome 6 Cancer Genetics and Cytogenetics. 84: 155. DOI: 10.1016/0165-4608(96)85307-6 |
0.408 |
|
| Show low-probability matches. |